2006
Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation
TRBUŠEK, Martin; Jitka MALČÍKOVÁ; Jana ŠMARDOVÁ; Viera KUHROVÁ; Dita MENTZLOVÁ et al.Základní údaje
Originální název
Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation
Název česky
Inaktivace p53 a delece ATM u B-CLL pacientů ve vztahu s IgVH
Autoři
TRBUŠEK, Martin; Jitka MALČÍKOVÁ ORCID; Jana ŠMARDOVÁ; Viera KUHROVÁ; Dita MENTZLOVÁ; Soňa BUKOVSKÁ; Petr KUGLÍK; Michael DOUBEK; Yvona BRYCHTOVÁ; Šárka POSPÍŠILOVÁ; Dana DVOŘÁKOVÁ; Jiří VORLÍČEK; Jiří MAYER; Miluše SVITÁKOVÁ; Věra LINKOVÁ; Jiří ZAČAL a Jitka KUJÍČKOVÁ
Vydání
Leukemia, 2006, 0887-6924
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 6.146
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/06:00019161
Organizační jednotka
Lékařská fakulta
UT WoS
Klíčová slova anglicky
B-CLL FASAY IgVH p53 ATM previous treatment
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 26. 7. 2010 13:20, RNDr. Jitka Malčíková, Ph.D.
V originále
Defects in either of the two cooperating tumor suppressors, p53 or ATM, confer an inferior prognosis for B CLL patients. The abnormalities were reported to be associated with the unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour. However a recent report has also clearly correlated the p53 inactivation to a DNA damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003, 10: 477 to 484). We performed a comprehensive determination of p53 status in 168 B CLL samples (including functional FASAY analysis) and a deletion screening of ATM locus in 69% of the corresponding samples and correlated the data to the IgVH mutation status and to previous treatment. Inactivation of the p53 (overall frequency 12%) occurred markedly more frequently (P 0.05) and deletions of ATM (overall frequency 18%) strictly (P 0.001) in the unmutated IgVH subtype. A statistically significant correlation was not achieved between the presence of previous treatment (including alkylating agents in 44/49 cases) and the p53 or ATM abnormalities. In the IgVH unmutated subgroup, where the treatment was markedly more frequent, the proportion of the defects was similar in untreated/treated groups of patients. The p53/ATM inactivation does not seem to be primarily a consequence of DNA damaging chemotherapy.
Česky
Defects in either of the two cooperating tumor suppressors, p53 or ATM, confer an inferior prognosis for B CLL patients. The abnormalities were reported to be associated with the unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour. However a recent report has also clearly correlated the p53 inactivation to a DNA damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003, 10: 477 to 484). We performed a comprehensive determination of p53 status in 168 B CLL samples (including functional FASAY analysis) and a deletion screening of ATM locus in 69% of the corresponding samples and correlated the data to the IgVH mutation status and to previous treatment. Inactivation of the p53 (overall frequency 12%) occurred markedly more frequently (P 0.05) and deletions of ATM (overall frequency 18%) strictly (P 0.001) in the unmutated IgVH subtype. A statistically significant correlation was not achieved between the presence of previous treatment (including alkylating agents in 44/49 cases) and the p53 or ATM abnormalities. In the IgVH unmutated subgroup, where the treatment was markedly more frequent, the proportion of the defects was similar in untreated/treated groups of patients. The p53/ATM inactivation does not seem to be primarily a consequence of DNA damaging chemotherapy.
Návaznosti
| NR8445, projekt VaV |
| |
| NR8448, projekt VaV |
|